Arcus Biosciences' ARC-10 lung cancer trial listed as completed as of Oct 2026 update

Arcus Biosciences' registry record for its NSCLC trial shows a status update on the study's completion.

• The trial, "A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer" (NCT04736173, ARC-10), is sponsored by Arcus Biosciences, Inc., with Gilead Sciences as a collaborator.¹ The registry lists overall status as completed, with primary completion and study completion both dated 2026-09-17, and a last update posted 2026-10-19.¹
• The study enrolled 169 participants¹ across a multi-arm design testing zimberelimab and domvanalimab in different combinations. In Part 1, patients were assigned to platinum-based chemotherapy with carboplatin, pemetrexed, and paclitaxel¹, zimberelimab monotherapy¹, or domvanalimab combined with zimberelimab¹. In Part 2, patients received either domvanalimab plus zimberelimab¹ or pembrolizumab¹.
• The primary outcome measured was progression-free survival, from randomization until death from any cause, up to 7 years¹, with secondary outcomes including overall survival, confirmed overall response rate, and treatment-emergent adverse events¹.